Some physicians have urged their colleagues and medical societies to move professional conferences out of states that ...

Gender-affirming hormone therapy may reduce the risk of prostate cancer in transgender women, but it may also increase the risk of biochemical recurrence and bone metastases in patients with prostate ...

The FDA has approved the Cologuard Plus test for colorectal cancer screening in adults age 45 years and older who are at average risk of colorectal cancer.

Female physicians remain underrepresented among residents entering high-compensation specialties, data suggest.

Atezolizumab did not improve overall survival, progression-free survival, distant metastasis-free survival, or time to local failure.

A 2023 survey showed that 24% of Americans who used online pharmacies had been exposed to harmful or substandard medications.